New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For KORS;NTWK;FOSL;AVP;BCS;ZIOP;VAL;LVLT;BYD;FB;QCOM From The Last 14 Days
Check below for free stories on KORS;NTWK;FOSL;AVP;BCS;ZIOP;VAL;LVLT;BYD;FB;QCOM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>
July 23, 2014
07:58 EDTFBFacebook July weekly volatility increases to 108 into Q2 and outlook
Subscribe for More Information
07:37 EDTQCOMQualcomm July weekly volatility elevated into Q3 and outlook
Subscribe for More Information
07:27 EDTQCOMQualcomm upgraded to Outperform from Market Perform at Northland
Subscribe for More Information
06:56 EDTFBNY court calls Facebook CEO to testify at forgery trial, Reuters says
Subscribe for More Information
July 22, 2014
16:00 EDTFBOptions Update; July 22, 2014
Subscribe for More Information
15:41 EDTQCOMQualcomm replaces NVIDIA in newest Xiaomi Mi phone, TechInAsia reports
Subscribe for More Information
15:39 EDTQCOMNVIDIA loses another Tegra socket to Qualcomm, says Pacific Crest
Subscribe for More Information
14:05 EDTFBFacebook enhances mobile targeting for developers
Subscribe for More Information
12:19 EDTQCOMQualcomm advances after Cowen sees shares poised to break-out
Shares of Qualcomm (QCOM), which develops mobile device components, are climbing after research firm Cowen wrote that the stock is poised to break-out above its recent range. WHAT'S NEW: Qualcomm's stock is well-positioned to advance above the trading range it has stayed in over the past three months, Cowen analyst Timothy Arcuri wrote in a note to investors earlier today. The company's Q3 results, due to be announced on July 23, should be in-line with or better than expectations, the analyst predicted. The company's QCT business unit - which provides solutions for smart connected devices - likely exceeded expectations last quarter, driven by gains in LTE technologies, according to Arcuri. Meanwhile, he believes that Qualcomm's technology licensing business should generate results at the high end of the unit's total available market, as its revenue from licensing technology for devices using the CDMA standard appears to have exceeded the high end of its guidance. Qualcomm's Q4 guidance could exceed expectations and the company's revenue growth may accelerate to double digit percentage levels, the analyst forecast. Furthermore, Qualcomm's profits are likely to be boosted by cost cutting and higher margins in its QCT business, Arcuri predicted. He kept an $86 price target and Outperform rating on the shares. PRICE ACTION: In early afternoon trading, Qualcomm climbed $2, or 2.5%, to $81.69.
10:00 EDTVALOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:36 EDTFBActive equity options trading on open
Subscribe for More Information
08:24 EDTQCOMQualcomm poised to break out of trading range, says Cowen
Subscribe for More Information
08:12 EDTLVLTLevel 3 announces planned executive management team
Subscribe for More Information
07:31 EDTBCSSenate Homeland Security & Government Affairs Committee to hold a hearing
Subscribe for More Information
07:16 EDTBCSBarclays plunges from 2nd to 12th in U.S. dark pool ranks after suit, FT says
Subscribe for More Information
07:15 EDTZIOPZiopharm announces expansion of oncology programs with Intrexon
Ziopharm (ZIOP) announced the expansion of synthetic immuno-oncology programs in conjunction with Intrexon (XON) to include chimeric antigen receptor T-cell, or CAR-T, therapy. Additionally the company has provided an update on its development efforts with the proprietary RheoSwitch Therapeutic System, or RTS, platform, an inducible regulator for expression of therapeutic molecules through administration of an oral activator ligand, as well as its clinical program with Ad-RTS-IL-12, a novel DNA-based therapeutic candidate for the controlled expression of IL-12. CAR-T cells represent an emerging, high value immunological therapy that can target and destroy cancer cells displaying "personalized" fingerprints, yet current approaches feature challenges associated with toxicity, off-target effects, and uneconomical manufacturing. Intrexon possesses the integrated technology platforms, molecular engineering, systems biology, and cell engineering capabilities required to overcome these challenges and fully realize the potential of CAR]T cell therapies. Most significantly, utilization of the RTS platform will facilitate exquisite regulation of one or more bioeffectors in CAR-T cells enabling physicians to control systemic effects of cell therapies with an appropriate dosing regimen of the oral activator ligand, and eventually bring about improved safety and efficacy of these and related therapeutic strategies. Further preclinical work is underway in this promising area of study, and ZIOPHARM and Intrexon expect to provide a progress update in the second half of 2014.
05:39 EDTVALValspar upgraded to Conviction Buy from Neutral at Goldman
Goldman Sachs upgraded Valspar to Conviction Buy from Neutral citing the valuation discount peers, the recovery in the U.S. housing market and momentum in the company's Australian business. The firm raised its price target for shares to $97 from $83.
05:27 EDTVALValspar upgraded to Conviction Buy from Neutral at Goldman
July 21, 2014
16:18 EDTLVLTNetflix says policy goal is for DOJ/FCC to block Comcast, TWC deal
Subscribe for More Information
16:00 EDTFBOptions Update; July 21, 2014
iPath S&P 500 VIX Short-Term Futures up 65c to 28.53. Option volume leaders: AAPL FB NFLX DG CMCSA GILD PBR TWTR TSLA according to Track Data.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use